Abstract
Background
The relationship between Kaposi’s sarcoma (KS) and psoriasis is still controversial.
Objectives
To analyse the association between KS and psoriasis, address the hypothesis of a reciprocal influence between the two conditions relative to clinical presentation and evolution, and consider the best therapeutic approach to be used for the treatment of psoriasis in KS patients in order to avoid the typical induction or worsening of KS during immunosuppression.
Materials & Methods
We retrospectively reviewed clinical records of 37 patients with KS and psoriasis. Fisher’s exact test was performed in order to compare epidemiological and clinical data between subsets of patients.
Results
The prevalence of psoriasis in our KS population (n = 1407) was 2.6%. There were no statistically significant differences in terms of stage or rate of progression between KS patients with and without psoriasis, except for a higher frequency of patients with KS Stage IIB among patients with KS and psoriasis (p = 0.001).
Conclusions
Patients with psoriasis have a risk of KS comparable to that of the general population. Psoriasis and KS do not appear to influence each other. For the treatment of psoriasis in KS patients, one should take into account the KS-inducing potential of certain anti-psoriatic drugs.
Similar content being viewed by others
References
Reich K. The concept of psoriasis as a systemic inflammation:implications for disease management. J Eur Acad Dermatol Venereol 2012; 26: 3–11.
Hanahan D, Weinberg RA. Hallmarks of cancer:the next generation. Cell 2011; 144: 646–74.
Pouplard C, Brenaut E, Horreau C, et al. Risk of cancer in psoriasis:a systematic review and meta–analysis of epidemiological studies. J Eur Acad Dermatol Venereol 2013; 27: 36–46.
Ganem D. KSHV and the pathogenesis of Kaposi sarcoma:listening to human biology and medicine. J Clin Invest 2010; 120: 939–49.
Tebbe B, Mayer–da–Silva A, Garbe C, von Keyserlingk HJ, Orfanos CE. Genetically determined coincidence of Kaposi sarcoma and psoriasis in an HIV–negative patient after prednisolone treatment. Spontaneous regression 8 months after discontinuing therapy. Int J Dermatol 1991; 30: 114–20.
Selvi E, De Stefano R, Manganelli S, Marcolongo R. Kaposi’s sarcoma in psoriatic arthritis. Rheumatology (Oxford) 2003; 42: 389.
Sorce M, Bongiorno MR. Simultaneous diagnosis of Kaposi’s sarcoma, psoriasis, vitiligo and monoclonal gammopathy of undetermined significance in an immunocompetent patient. J Dermatol 2013; 40: 479–80.
Fargnoli MC, Peris K, Frascione P, et al. Psoriasis. Kaposi’s sarcoma and Hodgkin’s disease in a patient with Down’s syndrome. Dermatology 2004; 209: 158–9.
Bielan B. What’s your assessment? Psoriasis with Kaposi sarcoma. Dermatol Nurs 2005; 17: 30–1.
Ursini F, Naty S, Mazzei V, Spagnolo F, Grembiale RD. Kaposi’s sarcoma in a psoriatic arthritis patient treated with infliximab. Int Immunopharmacol 2010; 10: 827–8.
Dervis E, Demirkesen C. Kaposi’s sarcoma in a patient with psoriasis vulgaris. Acta Dermatovenerol Alp Pannonica Adriat 2010; 19: 31–4.
Häring N, Strohal R, Kemmler N. Kaposi sarcoma in a psoriasis patient. J Dtsch Dermatol Ges 2012; 10: 65–6.
Philipp S, Kokolakis G, Hund M, et al. Immunological changes in psoriasis patients under long–term treatment with fumaric acid esters:risk of Kaposi sarcoma occurrence? Eur J Dermatol 2013; 23: 339–43.
Verdelli A, Bonciani D, Bonciolini V, Caproni M. Is tocilizumab safe in Kaposi sarcoma? A complex association among rheumatoid arthritis, psoriasis, and Kaposi sarcoma. Clin Drug Investig 2014; 34: 437–8.
Tyros G, Potouridou I, Tsaraklis A, et al. A generalized Kaposi’s sarcoma after chronic and extensive topical corticosteroid use. Eur J Dermatol 2014; 24: 111–2.
Florek AG, Eilers D, Armstrong AW. A case of Kaposi sarcoma in an immunocompetent, heterosexual Irish man:a discussion of etiology and viral transmission. Dermatol Online J 2015; 21: 10.
Yoo J, Jo M, Kim MS, Choi KH, Park HJ, Jue MS. Hidden pictures of Kaposi’s sarcoma in psoriatic lesions:a diagnostic challenge. Ann Dermatol 2016; 28: 749–52.
Taylor WJ, Gladman DD, Helliwell PS, et al. Classification criteria for psoriatic arthritis:results from the CASPAR study group. Arthritis Rheum 2006; 54: 2665–73.
Brambilla L, Boneschi V, Taglioni M, Ferrucci S. Staging of classic Kaposi sarcoma:a useful tool for therapeutic choices. Eur J Dermatol 2003; 13: 83–6.
Hemminki K, Liu X, Ji J, Sundquist J, Sundquist K. Kaposi sarcoma and Merkel cell carcinoma after autoimmune disease. Int J Cancer 2012; 131:e326–8.
Lowes MA, Suárez–Fari˜nas M, Krueger JG. Immunology of psoriasis. Annu Rev Immunol 2014; 32: 227–55.
Ensoli B, Stürzl M, Monini P. Reactivation and role of HHV–8 in Kaposi’s sarcoma initiation. Adv Cancer Res 2001; 81: 161–200.
Saggini A, Chimenti S, Chiricozzi A. IL–6 as a druggable target in psoriasis:focus on pustular variants. J Immunol Res 2014; 2014: 964069.
Miles SA, Testa M, Huang J, Wade M, Carden J, Scadden DT. Lack of tumor activity and intolerance of interleukin–4 in patients with advanced HIV disease and Kaposi’s sarcoma. J Interferon Cytokine Res 2002; 22: 1143–8.
Calcaterra F, Brambilla L, Colombo E, et al. Increased frequency and vasculogenic potential of endothelial colony–forming cells in patients with Kaposi’s sarcoma. J Invest Dermatol 2017; 137: 1533–40.
Boyman O, Conrad C, Dudii C, Kielhorn E, Nickoloff BJ, Nestle FO. Activation of dendritic antigen–presenting cells expressing common heat shock protein receptor CD91 during induction of psoriasis. Br J Dermatol 2005; 152: 1211–8.
Della Bella S, Nicola S, Brambilla L, et al. Quantitative and functional defects of dendritic cells in classic Kaposi’s sarcoma. Clin Immunol 2006; 119: 317–29.
Cappelletti M, Presicce P, Calcaterra F, Mavilio D, Della Bella S. Bright expression of CD91 identifies highly activated human dendritic cells that can be expanded by defensins. Immunology 2015; 144: 661–7.
Tan Y, Wang Y, Li L, Xia J, Peng S, He Y. Chemokinelike factor 1–derived C–terminal peptides induce the proliferation of dermal microvascular endothelial cells in psoriasis. PLoS One 2015; 10:e0125073.
Samaniego F, Markham PD, Gendelman R, et al. Vascular endothelial growth factor and basic fibroblast growth factor present in Kaposi’s sarcoma (KS) are induced by inflammatory cytokines and synergize to promote vascular permeability and KS lesion development. Am J Pathol 1998; 152: 1433–43.
Seçkin D, Ozcan G, Demirăg A, Hizel N, Haberal M. The Koebner phenomenon in Kaposi’s sarcoma in a renal transplant recipient. Br J Dermatol 1998; 139: 346–8.
Saraceno R, Mannheimer R, Chimenti S. Regional distribution of psoriasis in Italy. J Eur Acad Dermatol Venereol 2008; 22: 324–9.
Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am 2015; 41: 545–68.
Schwartz RA, Micali G, Nasca MR, Scuderi L. Kaposi sarcoma:a continuing conundrum. J Am Acad Dermatol 2008; 59: 179–206.
Kwon HH, Kwon IH, Youn JI. Clinical study of psoriasis occurring over the age of 60 years:is elderly–onset psoriasis a distinct subtype? Int J Dermatol 2012; 51: 53–8.
Brambilla L, Tourlaki A, Genovese G. Iatrogenic Kaposi’s sarcoma:a retrospective cohort study in an Italian tertiary care centre. Clin Oncol (R Coll Radiol) 2017; 29:e165–71.
Wall D, McMenamin M, O’Mahony D, Irvine AD. Kaposi sarcoma in a patient with atopic dermatitis treated with ciclosporin. BMJ Case Rep 2013;2013.
Tartar D, Bhutani T, Huynh M, Berger T, Koo J. Update on the immunological mechanism of action behind phototherapy. J Drugs Dermatol 2014; 13: 564–8.
Wong T, Hsu L, Liao W. Phototherapy in psoriasis:a review of mechanisms of action. J Cutan Med Surg 2013; 17: 6–12.
Nakamura S, Salahuddin SZ, Biberfeld P, et al. Kaposi’s sarcoma cells:long–term culture with growth factor from retrovirus–infected CD4+ T cells. Science 1988; 242: 426–30.
Cohen CD, Horster S, Sander CA, Bogner JR. Kaposi’s sarcoma associated with tumour necrosis factor alpha neutralising therapy. Ann Rheum Dis 2003; 62: 684.
Bret J, Hernandez J, Aquilina C, Zabraniecki L, Fournie B. Kaposi’s disease in a patient on adalimumab for rheumatoid arthritis. Joint Bone Spine 2009; 76: 721–2.
Martínez–Martínez ML, Pérez–García LJ, Escario–Travesedo E, Ribera–Vaquerizo PA. Kaposi sarcoma associated with infliximab treatment. Actas Dermosifiliogr 2010; 101: 462–4.
Amadu V, Satta R, Montesu MA, Cottoni F. Kaposi’s sarcoma associated with treatment with adalimumab. Dermatol Ther 2012; 25: 619–20.
Corbeil J, Rapaport E, Richman DD, Looney DJ. Antiproliferative effect of retinoid compounds on Kaposi’s sarcoma cells. J Clin Invest 1994; 93: 1981–6.
Caselli E, Galvan M, Santoni F, et al. Retinoic acid analogues inhibit human herpesvirus 8 replication. Antivir Ther 2008; 13: 199–209.
Morganroth GS. Topical 0.1% alitretinoin gel for classic Kaposi sarcoma. Arch Dermatol 2002; 138: 542–3.
Bodsworth NJ, Bloch M, Bower M, Donnell D, Yocum R, & International Panretin Gel KS Study Group. Phase III vehicle–controlled, multi–centered study of topical alitretinoin gel 0.1% in cutaneous AIDSrelated Kaposi’s sarcoma. Am J Clin Dermatol 2001; 2: 77–87.
Rongioletti F, Zaccaria E, Viglizzo G. Failure of topical 0.1% alitretinoin gel for classic Kaposi sarcoma:first European experience. Br J Dermatol 2006; 155: 856–7.
Robey RC, Bower M. Facing up to the ongoing challenge of Kaposi’s sarcoma. Curr Opin Infect Dis 2015; 28: 31–40.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
About this article
Cite this article
Brambilla, L., Genovese, G., Tourlaki, A. et al. Coexistence of Kaposi’s sarcoma and psoriasis: is there a hidden relationship?. Eur J Dermatol 28, 320–325 (2018). https://doi.org/10.1684/ejd.2018.3288
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1684/ejd.2018.3288